Funded Tech Companies
FundaMental Pharma
Headquartered in Heidelberg, FundaMental Pharma has funding from Thuja Capital, BioGeneration Ventures and High-Tech Gründerfonds.
Company Overview
Company Name
FundaMental Pharma
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Im Neuenheimer Feld 582
Heidelberg, D-69120
DE
Heidelberg, D-69120
DE
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
The FundaMental Pharma Team harnesses the power of this revolutionary discovery of a new drug class to stop loss of brain structure and thus loss of function. FundaMental Pharma GmbH is a neuroscience company with portfolio at the preclinical stage, which was spun out of the Department of Neurobiology at Heidelberg University, Germany. First-in class NMDAR/TRPM4 (N/T) Interface Inhibitors selectively abolish extrasynaptic NMDARs-induced glutamate neurotoxicity but preserve the effects of synaptic NMDARs on neuronal survival and memory. N/T interface inhibition has the potential to stop neurodegeneration, to restore neuronal function, and to maintain brain health. N/T interface inhibitors provide neuroprotection through selective elimination of toxic extra synaptic NMDARs signaling.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
11/21/2022
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Thomas Schulze
Chief Medical Officer
Gabriele Barth
Company Investors
Browse more funded tech companies:
Fundamental Applied Biology | FundamentalVR
Share this article
About Our VC Transaction Database
This tech company profile is powered by VentureDeal.com, a market leader in private equity transaction data.
Additional Resources for Entrepreneurs